Last month French biotech Dynacure dosed the first patient in an early-stage trial of its lead drug candidate, a treatment for a group of rare genetic muscle disorders.
Now the company, which also has an office in Philadelphia, has landed a €50 million ($55 million) Series C financing round to move that investigational antisense medicine, DYN101, through a Phase 1/2 trial in adults with one of a number of forms of centronuclear myopathy (CNM). The group of disorders is characterized by muscle weakness and wasting, which when severe can be life-threatening.
Dynacure, a spinoff of the Institute of Genetic and Molecular… Read more »
UNDERWRITERS AND PARTNERS
